Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.
Also called NCT07193459
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Registry
-
NCT07193459
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07193459. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-12 (actual); primary completion 2026-10-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HDM1002 200 mg
- Intervention (Drug)
- HDM1002 400 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07193459- Content hash
d452b495a2e0b1e6410f980a91ab36d0316a926fe6f789c1c0ffdbd6e34515d9